Bomb Report – Lifestyle
Author:
Opus Genetics, Inc.
Opus Genetics to Participate in Leading Medical Conferences in May 2026
April 27, 2026
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
April 6, 2026
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
March 24, 2026
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
March 10, 2026
Opus Genetics to Present at Upcoming Investor Conferences in March 2026
March 6, 2026
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
March 6, 2026
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
March 5, 2026